Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122614892 | 12261489 | 2 | F | 2008 | 20160630 | 20160412 | 20160708 | EXP | US-ASTRAZENECA-2012SE74302 | ASTRAZENECA | 58.00 | YR | M | Y | 77.10000 | KG | 20160709 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122614892 | 12261489 | 1 | PS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | U | U | 21366 | TABLET | ||||||||
| 122614892 | 12261489 | 2 | SS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | U | U | 21366 | TABLET | ||||||||
| 122614892 | 12261489 | 3 | SS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | U | U | 21366 | 10 | MG | TABLET | QD | |||||
| 122614892 | 12261489 | 4 | C | LISINOPRIL. | LISINOPRIL | 1 | Oral | 0 | 5 | MG | QD | ||||||||
| 122614892 | 12261489 | 5 | C | METFORMIN HCL | METFORMIN HYDROCHLORIDE | 1 | 0 | 500 | MG | BID | |||||||||
| 122614892 | 12261489 | 6 | C | LOPID | GEMFIBROZIL | 1 | 0 | 600 | MG | BID | |||||||||
| 122614892 | 12261489 | 7 | C | PLAVIX | CLOPIDOGREL BISULFATE | 1 | 0 | 75 | MG | BID | |||||||||
| 122614892 | 12261489 | 8 | C | JANUVIA | SITAGLIPTIN PHOSPHATE | 1 | 0 | 100 | MG | QD | |||||||||
| 122614892 | 12261489 | 9 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | 0 | ||||||||||||
| 122614892 | 12261489 | 10 | C | CIPRO | CIPROFLOXACIN HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 122614892 | 12261489 | 11 | C | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 122614892 | 12261489 | 12 | C | HYTRIN | TERAZOSIN HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 122614892 | 12261489 | 13 | C | ASPIRIN. | ASPIRIN | 1 | 0 | ||||||||||||
| 122614892 | 12261489 | 14 | C | LORATADIN | LORATADINE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122614892 | 12261489 | 1 | Blood cholesterol increased |
| 122614892 | 12261489 | 2 | Blood cholesterol increased |
| 122614892 | 12261489 | 3 | Blood cholesterol increased |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122614892 | 12261489 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122614892 | 12261489 | Coronary artery disease | |
| 122614892 | 12261489 | Diabetic neuropathy | |
| 122614892 | 12261489 | Myocardial infarction | |
| 122614892 | 12261489 | Type 2 diabetes mellitus |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122614892 | 12261489 | 1 | 200801 | 201112 | 0 | |
| 122614892 | 12261489 | 2 | 2009 | 0 | ||
| 122614892 | 12261489 | 3 | 20110207 | 0 | ||
| 122614892 | 12261489 | 4 | 2008 | 0 | ||
| 122614892 | 12261489 | 5 | 2008 | 0 | ||
| 122614892 | 12261489 | 7 | 2008 | 0 | ||
| 122614892 | 12261489 | 8 | 2008 | 0 | ||
| 122614892 | 12261489 | 9 | 201103 | 2012 | 0 |